The present proposal is an innovative and translational clinical trial derived from exciting
preclinical findings to test the hypothesis that treatment with the melanocortin activator
bupropion can reduce binge drinking in humans. Furthermore, pilot data on moderating effects
of coexisting nicotine use on the efficacy of bupropion for binge drinking population will be
obtained. Evidence for an efficacy signal with good tolerability with this FDA approved
medication would form the foundation to conduct a well-powered Phase II b trial. The
development of an effective pharmacotherapy for binge drinking would be a significant
clinical advance.
.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)